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Abstract⎯Activating mutations in the EGFR gene influence cell proliferation, angiogenesis, and increases
metastatic ability of non-small cell lung cancer (NSCLC) cells; they have a significant impact on the choice
of medical therapy of NSCLC. The use of targeted therapy with tyrosine kinase inhibitors requires perfor-
mance of appropriate genetic tests in NSCLC patients. The aim of this study was to develop a real-time PCR-
based diagnostic test-system for rapid and cost-effective analysis of EGFR mutations in paraffin blocks and
plasma and to perform comparative estimation of diagnostic characteristics features of real-time wild type
blocking PCR and digital PCR. The study included 156 patients with different degrees of lung adenocarci-
noma differentiation. A simple and efficient real-time PCR-based method for detection of L858R activating
mutation and del19 deletion in the EGFR gene in DNA isolated from paraffin blocks or blood has been devel-
oped. The test system for EGFR mutations has been validated using 411 samples of paraffin blocks. The pro-
posed system demonstrated high efficiency for DNA testing from paraffin blocks: a concordance with results
of testing by means a Therascreen® EGFR RGQ PCR Kit (Qiagen, Germany) was 100%. Applicability of
this test system has been also demonstrated for detection of mutations in plasma.
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INTRODUCTION
The EGFR gene encodes the epidermal growth fac-
tor receptor (EGFR), a transmembrane glycoprotein,
a member of the receptor tyrosine kinase family.
EGFR influences angiogenesis, proliferation, and
increases metastatic activity of cells [1, 2]. The pres-
ence of mutations in the EGFR gene results in receptor
dimerization, autophosphorylation of its intracellular
tyrosine kinase domain and activation of MAPK and
PI3K/Akt signaling pathways [3]. Phosphorylated
proteins, in turn, activate transcription factors that
regulate synthesis of mRNA and proteins [4]. Most of
the somatic mutations of the EGFR gene found in
patients with non-small cell lung cancer (NSCLC) are
localized in the exons 18–21 encoding the tyrosine
kinase domain [5, 6]. In this context mutations associ-
ated with susceptibility to tyrosine kinase inhibitors
(ITK) are especially interesting. These mutations are:
deletions in exon 19 (del19), which may be of different
sizes [3], L858R replacement in exon 21 [7, 8], and
also mutations associated with resistance to ITK, for
example, the T790M mutation in exon 20 [7–9].
One of the first methods used for determining
somatic mutations in the EGFR gene was Sanger
sequencing, which involved analysis of the whole cod-
ing region [10]. However, this method has a low sensi-
tivity (about 20% of the mutant DNA content in the
sample), so more sensitive methods based on direct
analysis of mutations and deletions of the EGFR gene
have been developed [11, 12]. Current methods for the
analysis of somatic mutations represent either targeted
gene sequencing, or whole genome/whole-exome
sequencing [13, 14]. However, these methods are
expensive, and existing test systems of Russian manu-
facturers are not adapted for routine use in clinical
diagnostic laboratories.
It should be also noted modern molecular genetic
studies use mostly DNA isolated directly from the
tumor tissue. The surgical material is usually available
for analysis, but detection of mutations in biopsy
